Statement of Principles concerning allergic contact dermatitis (Balance of Probabilities) (No. 2 of 2021)

Allergic contact dermatitis is defined substantively in subsection 7(2) as inflammation of an area of skin from exposure to an allergen that has been applied to the same area, being a cell‑mediated delayed‑type hypersensitivity reaction due to a substance to which the individual has been previously sensitised. It includes dermatitis from airborne allergens but expressly excludes atopic dermatitis (eczema), irritant contact dermatitis, metal‑implant hypersensitivity, photocontact dermatitis, systemic allergic dermatitis and urticaria. The note clarifies that it typically presents as an eczematous rash on exposed skin, including cheilitis and periorbital involvement. The ICD‑10‑AM code L23 is assigned but the definition in the instrument governs, not the code. Death from allergic contact dermatitis includes death from a terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function) contributed to by the condition.

Allergen is defined in the dictionary as a substance capable of producing an immune response and inflammation in an area of skin, with a non‑exhaustive list of 14 examples: balsam of Peru, basic red dye, bufexamac, chromium, disperse dyes, epoxy resin, formaldehyde or its releasers, fragrances, fuels or oils, nickel, rubber accelerators, tea tree oil, topical benzocaine and topical neomycin. The list is illustrative only; any substance meeting the definition qualifies.

Sensitising exposure to an allergen (added by the 2022 amendment) means an exposure without symptoms, where the clinical onset of allergic contact dermatitis occurs within two weeks of a subsequent exposure to the same allergen. This recognises that initial sensitisation may be asymptomatic and that the condition only becomes clinically apparent upon re‑exposure. The note states that the sensitising exposure may be systemic or cutaneous and may have occurred months to years before the re‑exposure.

Relevant service is defined narrowly in the dictionary: it means eligible war service (other than operational service) under the VEA, defence service (other than hazardous service and British nuclear test defence service) under the VEA, or peacetime service under the MRCA. This is critical: operational service (combat or warlike service), hazardous service and British nuclear test defence service are excluded from this SoP. Claims from veterans with those kinds of service are governed by different standards under the VEA (the reasonable hypothesis standard rather than balance of probabilities) or other SoPs. The consequence is that this instrument applies predominantly to peacetime or non‑hazardous service veterans, such as those who served in Australia during peacetime or in non‑combat roles.

Balance of probabilities standard is embedded in the instrument’s title and basis (section 8). The RMA must be satisfied that it is more probable than not that the condition can be related to relevant service. This is a lower threshold than beyond reasonable doubt but higher than reasonable hypothesis. The factors are the exclusive pathway for establishing that probability. The instrument does not require medical certainty; it requires the decision‑maker to accept the factor as sufficient unless evidence to the contrary is compelling.

Clinical onset and clinical worsening are not defined but must be interpreted as the first manifestation of symptoms sufficient to warrant a diagnosis, and a material deterioration respectively. The two‑week window for allergen exposure before onset or worsening is a strict temporal criterion. For sensitising exposure (factor 1A), the re‑exposure must occur within two weeks of onset; the initial sensitising exposure can be much earlier.

Cross‑sensitisation is noted in the notes to subsections 9(1) and 9(2): a person sensitised to one allergen may react to a chemically similar allergen. This potentially broadens the exposure requirement - the allergen in question need not be the exact substance that caused the initial sensitisation, as long as cross‑reaction occurs. The dictionary definition of allergen is sufficiently broad to encompass cross‑reactants.

Terminal event is defined in the dictionary as the proximate or ultimate cause of death and includes five specific causes: pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function. This is a closed list. For a death claim, the person’s allergic contact dermatitis must have contributed to one of those terminal events. The instrument does not quantify the degree of contribution.

The instrument directly affects three groups. First, veterans and members of the Australian Defence Force (ADF) who render relevant service as defined. Relevant service excludes operational, hazardous and British nuclear test defence service, so the primary beneficiaries are those who served in peacetime or non‑operational roles - for example, ADF members who served in Australia or non‑warlike deployments. The instrument also covers former members who had defence service under the VEA (continuous full‑time service after 1972) and members with peacetime service under the MRCA. Their legal representatives, medical practitioners and expert witnesses must understand the factors to present or contest claims. The instrument’s three factors give these claimants a structured pathway to establish causation, but failure to satisfy any factor will likely defeat the claim.

Second, the instrument binds decision‑makers within the Department of Veterans’ Affairs (DVA), the Veterans’ Review Board and the Administrative Appeals Tribunal. Under s196B(3) of the VEA, the RMA’s SoPs are legislative instruments that delegate‑decision makers must apply. This reduces their discretion but also provides a clear checklist, which can streamline processing. The cost to DVA is a loss of flexibility to consider individual medical nuances outside the factors. The benefit is consistency across claims and reduced litigation risks. The instrument also affects the RMA itself, which is obliged to review and amend SoPs when new medical‑scientific evidence emerges. The 2022 amendment demonstrates active maintenance.

Third, the instrument indirectly affects taxpayers and the Commonwealth budget. Because it facilitates certain claims that might otherwise fail, it increases the probability of compensation payouts. Conversely, by narrowing the causal pathways to three factors, it may block claims that rely on less common or less scientifically established mechanisms. The net fiscal effect depends on the frequency of claims and the ease of proving exposure. The instrument also affects the medical‑legal industry: dermatologists, occupational physicians and toxicologists are called upon to provide evidence on sensitisation, allergens and timing. The explicit list of examples in the dictionary may narrow disputes but also raises the bar for claimants with other allergens not listed.

Finally, the instrument’s definition of relevant service excludes a large cohort - those with operational service. Those veterans are covered by a different SoP (the reasonable hypothesis standard) or by the VEA’s alternative causation rules. This creates a two‑tier system: peacetime veterans must meet the balance‑of‑probabilities factors, while operational veterans have a lower threshold. The instrument therefore affects the relative equality of access to compensation.

The instrument does not impose direct duties on any person. Instead, it specifies rights for claimants: the right to have their claim assessed using the factors as the benchmark for causation. If a claimant can demonstrate that at least one factor exists and that it is related to their relevant service, the decision‑maker must accept that the condition is connected to service (subject to any contrary evidence meeting the higher standard of proof). The instrument thus confers a presumptive right to compensation, though the ultimate decision remains with DVA.

The primary duty lies with the RMA: under section 196B(3) of the VEA, the RMA must determine SoPs that reflect the current state of medical‑scientific knowledge. The instrument states it is made under that subsection. The RMA also has a duty to review and amend SoPs when new evidence arises, as the 2022 amendment illustrates. The instrument’s section 8 records the RMA’s view that the factors are based on “sound medical‑scientific evidence” and that it is more probable than not that the condition can be related to relevant service. This is a statement of the RMA’s satisfaction, which is conclusive for the purposes of the instrument.

Decision‑makers have a duty to apply the instrument. Under s120B(3) of the VEA and s339(3) of the MRCA, a determination must be in accordance with the relevant SoP. This means they cannot disregard the factors or substitute their own medical judgment unless they find that the SoP is not applicable or that the evidence does not support the factor. The instrument does not give decision‑makers a discretion to waive the factor requirements. However, the obligation is not absolute if there is a question of whether the factor is “related to service” - that issue remains a factual determination for the decision‑maker, guided by the factor’s own content.

Claimants have the right to present evidence of exposure, sensitisation, clinical onset or worsening, and inability to obtain management. They do not have a duty to prove causation beyond the balance of probabilities, but they must satisfy the factor requirements. There is no duty to submit to medical examination, but failure to provide evidence will result in the claim failing. The instrument also implies a right to rely on cross‑sensitisation (notes to subsections 9(1) and 9(2)). The dictionary’s non‑exhaustive allergen list gives claimants a starting point for evidence, but it does not limit them to those examples.

Section 11 provides that if a factor refers to an injury or disease covered by another SoP, the factors in that other SoP apply as in force from time to time. This incorporates by reference other SoPs, imposing a cross‑referencing duty on decision‑makers and claimants to identify and satisfy those other instruments. This can increase complexity if a factor requires showing, for example, “an inability to obtain appropriate clinical management” that relates to a different condition.

The instrument contains no penalty provisions. It is a legislative instrument that establishes evidentiary standards, not a regulatory code requiring compliance with prohibitions. There are no fines, criminal sanctions or administrative penalties for failing to adhere to its provisions. Enforcement mechanisms lie in the underlying VEA and MRCA, which govern claims adjudication.

If a decision‑maker fails to apply the SoP correctly, the remedy is internal review, merits review by the Veterans’ Review Board or the Administrative Appeals Tribunal, and ultimately judicial review by the Federal Court. A claimant can challenge a decision that incorrectly disregarded a factor or misapplied the definitions. The instrument itself provides no separate right of review; it operates within the existing structures of the VEA and MRCA. The practical consequence of non‑application is that the decision‑maker may be found to have made an error of law, and the decision may be set aside.

There is no penalty for a claimant who misrepresents evidence regarding exposure or sensitisation. However, the usual provisions of the Criminal Code concerning fraud against the Commonwealth would apply if a person knowingly provides false documents. The instrument does not create a strict liability offence for inaccurate claim materials; it merely sets out the factors that must be “exist” on the balance of probabilities. The RMA itself bears no penalty if its factors are later shown to be medically inaccurate; the VEA requires the RMA to keep SoPs under review but does not impose sanctions for errors.

The 2022 amendment was made under the Legislation Act 2003 (Cth), which requires registration and tabling but no penalty for breaching the primary Act. The instrument’s authority derives from s196B(3) of the VEA, and if the RMA were to act outside power (for example, by including a factor not supported by sound medical‑scientific evidence), the instrument could be disallowed by Parliament or struck down by a court on ultra vires grounds. That is a consequence of invalidity, not a penalty. The practical enforcement burden falls on claimants and their representatives to ensure DVA adheres to the SoP. There is no proactive enforcement body.

The instrument is made under the VEA and operates as a delegated legislative instrument within that statutory framework. Its primary interaction is with sections 120B (VEA) and 339 (MRCA), which require that a determination about a condition be made in accordance with any applicable SoP. The instrument does not replace the VEA or MRCA; it supplements them by providing a specific causation rule for allergic contact dermatitis. For claims under the VEA involving operational service, the reasonable hypothesis standard applies instead of the balance of probabilities, and this instrument is expressly limited to “relevant service” that excludes operational service. Therefore, operational service claims are not governed by this SoP; they fall under different SoPs or the default provision of s120(1) of the VEA.

Section 11 of the instrument incorporates other SoPs by reference. If a factor in section 9 refers to an injury or disease for which another SoP has been determined under s196B(3), the factors in that other SoP apply as in force from time to time. For example, if the factor “inability to obtain appropriate clinical management for allergic contact dermatitis” leads to a secondary condition such as depression, and a SoP exists for depression, the depression factor must also be satisfied. This creates a chain of causation that cross‑links multiple SoPs, increasing compliance complexity. The instrument does not list which other SoPs may be relevant; it leaves that to the circumstances.

The instrument also interacts with the Military Rehabilitation and Compensation Act 2004 (MRCA). Section 339 of the MRCA mirrors s120B of the VEA. The definition of “relevant service” in this SoP includes peacetime service under the MRCA. Claimants under the MRCA with peacetime service must therefore meet the same factors as VEA claimants with similar service types. However, the MRCA has its own definitions of “service injury or disease” and causation provisions; the SoP operates within that framework.

The instrument uses the ICD‑10‑AM (Tenth Edition) for reference but explicitly overrides it: subsection 7(3) states that the meaning of allergic contact dermatitis in the SoP governs, not the ICD code. This prevents confusion if the ICD code changes or is inconsistently applied by clinicians. The instrument also interprets the term “terminal event” by listing five specific causes, which may diverge from general usage in coronial or medical certification. That definition binds decision‑makers, overriding any broader medical understanding of terminal event. This interaction with general law is significant: a death certificate stating “terminal event” in a different manner must still be measured against the definition.

Finally, the instrument interacts with the Legislation Act 2003 (Cth) for registration, tabling and potential disallowance. The amendment history shows that sections 2 and 4 of the original instrument were repealed by operation of the Legislation Act (section 48D and 48C), suggesting those sections dealt with commencement or automatic expiry. This demonstrates that standardised Parliamentary oversight provisions apply.

The instrument originally commenced on 25 January 2021 as the Statement of Principles concerning allergic contact dermatitis (Balance of Probabilities) (No. 2 of 2021) (F2021L00033). It was amended by the Amendment Statement of Principles concerning allergic contact dermatitis (Balance of Probabilities) (No. 89 of 2022) (F2022L01114), registered on 26 August 2022 and commencing on 19 September 2022. The amendment made three substantive changes. First, it substituted subsections 9(1) and 9(2) (the two‑week exposure factors). The original wording is not preserved in the compilation, but the current text requires exposure “within the two weeks before the clinical onset” and “within the two weeks before the clinical worsening”. The substitution may have clarified the timing or the language. Second, it inserted a new subsection 9(1A) - having a sensitising exposure to an allergen before clinical onset, with onset within two weeks of a subsequent exposure. This added a second pathway for onset that recognises asymptomatic sensitisation. Third, it added the definition of “sensitising exposure to an allergen” to the Schedule 1 Dictionary.

The amendment history endnote also records that sections 2 and 4 were repealed by operation of the Legislation Act sections 48D and 48C respectively. Section 2 typically deals with commencement; section 4 may have dealt with something like “revocation” or “application”. The Legislation Act automatically repeals certain provisions after a period if they are spent. This suggests the original instrument may have had a sunset or transitional provision that expired. The compiled instrument now has no section 2 or 4.

No other amendments have occurred. The legislative history endnote shows only two instruments listed: the original and the amendment. The compilation date is 19 September 2022. There is no indication of any further amendments up to that date. The absence of multiple amendment rounds suggests the SoP is stable and that the 2022 amendment was significant. The sensible inference is that the RMA decided to add the sensitising exposure factor after accumulating medical‑scientific evidence that the original two‑week factor alone was insufficient to capture cases where the sensitising exposure occurred during service but the triggering exposure occurred later.

The amendment history is simple, but practitioners must be aware that only the current version (this compilation) is binding. Use of the pre‑amendment version would be an error of law. Since the amendment replaced the original subsections 9(1) and (2), the earlier text is no longer operative. The addition of factor 1A means that any claim assessed under the old SoP during the period from 25 January 2021 to 18 September 2022 would have had a narrower causation path. Claims made after 19 September 2022 benefit from the broader factor.

The source document does not refer to any specific litigation concerning this SoP. It contains no case names, judgments, or tribunal decisions. The instrument is a legislative instrument and as such is subject to judicial review, but the compilation provides no mention of any court challenges. This is consistent with the nature of SoPs: they are often challenged indirectly through appeals of claim decisions rather than direct invalidity proceedings. However, the absence of cited cases in the instrument itself does not mean the SoP has never been litigated. The instrument is silent on its own litigation history.

Given the source limitations, I cannot name cases that the source does not name. I can only state what the source says: nothing about litigation. In practice, veterans’ SoPs have been the subject of many Administrative Appeals Tribunal and Federal Court decisions, but those decisions are not part of this instrument and cannot be assumed. The instrument’s definition of relevant service (excluding operational service) may have been tested in the context of claims, but no such case is recorded here.

The 2022 amendment may have been prompted by a tribunal or court decision that pointed out a gap in the original factors. Again, no evidence in the source. The amendment history does not refer to any case. Therefore, any discussion of litigation history beyond the source would be speculation and must be avoided. The safest statement is that the source contains no information about litigation concerning this instrument. This is itself a useful observation: the instrument has apparently operated without a reported challenge to its validity, though its application may have been contested in individual cases. Practitioners should search independently for AAT decisions citing this SoP, but that research lies outside the scope of this deep dive.

Several traps can affect claimants and practitioners. First, the definition of relevant service excludes three categories: eligible war service that is operational service, defence service that is hazardous service, and British nuclear test defence service. A veteran who rendered operational service (e.g., in a combat zone) cannot rely on this SoP. Their claim will be assessed under the reasonable hypothesis standard, and a separate SoP may exist. If a practitioner mistakenly uses this SoP for an operational veteran, the claim may be misdirected. Second, the two‑week window in factors 1 and 2 is strict. Exposure must occur within 14 days before clinical onset or worsening. If the exposure occurred 15 days earlier, the factor is not met unless factor 1A (sensitising exposure) applies. For factor 1A, the sensitising exposure can be years earlier, but the re‑exposure that triggers onset must be within two weeks. Proving the precise date of onset and exposure can be difficult, especially for conditions with gradual onset. Medical records may lack precise dates.

Third, factor 3 (inability to obtain appropriate clinical management) applies only to material contribution or aggravation, not to initial onset. Section 10(2) confirms that factors 2 and 3 apply only where the condition was suffered or contracted before or during (but did not arise out of) relevant service. This means factor 3 cannot be used to establish a new claim for first‑onset allergic contact dermatitis; it only covers worsening. Fourth, the dictionary’s definition of allergen includes “examples”, but a claimant may need to prove that the substance to which they were exposed falls within the definition. For instance, an exposure to a rare industrial chemical not listed may still qualify, but the burden of proof is on the claimant to show it is capable of producing an immune response and inflammation. Without expert evidence, the decision‑maker may reject the claim. Fifth, the note on cross‑sensitisation is not a factor itself - it does not relax the two‑week rule. It only explains that exposure to a cross‑reacting allergen may satisfy the factor if the person was previously sensitised to a different allergen. Proving the cross‑sensitisation mechanism may require specialist dermatological evidence, increasing costs.

Sixth, the instrument uses “clinical onset” and “clinical worsening” without definitions. The settled tribunal interpretation is that clinical onset means the first time symptoms become manifest such that a diagnosis could be made. For worsening, the baseline must be established. If a claimant had pre‑existing dermatitis, the worsening must be measured against the pre‑existing severity. The instrument does not specify the degree of worsening required; any material deterioration may suffice, but the factor requires exposure within two weeks before that deterioration. Seventh, the definition of terminal event is a closed list. Death from an infection that is not pneumonia, or from multi‑organ failure that does not fit the five enumerated causes, may not satisfy the definition, even if allergic contact dermatitis contributed. Claim representatives should ensure the medical report identifies the terminal event as one of the listed causes.

Eighth, the factor of “inability to obtain appropriate clinical management” is inherently vague. What constitutes “appropriate clinical management” is not defined. It could include inability to access topical corticosteroids, avoidance advice, or patch testing. The factor does not require that the inability be due to service; it only requires the factor itself to be related to service (per s10). This creates a circular problem: if the inability arises because the person is on defence service and cannot see a civilian dermatologist, that may relate to service. But the link must be proven. Ninth, the amendment history shows that sections 2 and 4 were repealed. If a practitioner relies on the original instrument without checking the compilation, they might think those sections still exist. Always use the compiled version. Tenth, the instrument applies to claims under the MRCA for peacetime service only. A member with warlike service under MRCA is excluded. Finally, note that section 11 incorporates other SoPs by reference. If a factor leads to another condition (e.g., secondary infection), the claimant may need to satisfy a separate SoP for that condition, which may have different factors and standards.

For claimants and their representatives, compliance means ensuring that the claim clearly identifies which factor(s) are relied upon and that the evidence meets the instrument’s criteria. The first step is to confirm that the veteran or member has “relevant service” as defined. If they have operational service, this SoP does not apply. If they have peacetime service, proceed. The next step is to obtain a definitive diagnosis of allergic contact dermatitis that matches the definition in s7(2) - excluding atopic, irritant, metal‑implant, photo‑contact, systemic and urticarial dermatitis. A dermatologist’s report should specify the allergen and confirm the mechanism (delayed‑type hypersensitivity). The report should also state the date of clinical onset (or worsening) and, if relevant, the date of exposure and the date of any sensitising exposure.

For factor 1 (onset within two weeks of exposure), the claimant must provide evidence of the allergen exposure and the timing. This may involve witness statements, service records (e.g., use of creams, exposure to fuels in the workplace), or photographic evidence of the rash after use of a product. The allergen must be one that is capable of producing allergic contact dermatitis; using the dictionary’s list as a checklist is prudent. Note 2 about cross‑sensitisation can be invoked if the direct allergen is not obviously the trigger, but expert evidence on the chemical relationship is needed.

For factor 1A (sensitising exposure), the claimant must prove two exposures: an initial asymptomatic sensitising exposure, and a subsequent exposure within two weeks of onset. The initial exposure may have occurred months or years before service or during service. The key is that the factor (the sensitising exposure) must be related to service. Therefore, if the sensitising exposure happened during civilian life, the factor does not relate to service, and the claim fails. Evidence must show that the sensitising exposure occurred during relevant service. The subsequent re‑exposure that triggered onset may be civilian, but the factor is the sensitising exposure. This is a common trap: the sensitising exposure is the factor, not the re‑exposure.

For factor 2 (worsening within two weeks of exposure), the claimant must establish a baseline of the condition before the worsening. Medical records from before the service period or earlier in service are needed. The worsening must be clinically demonstrable, not merely subjective. For factor 3 (inability to obtain appropriate clinical management), the claimant must show that they could not access proper treatment (e.g., avoidance of allergens, topical therapy) and that this inability contributed to the worsening. Evidence could include statements from medical officers about lack of supplies or inability to refer to a dermatologist. This factor only applies to aggravation, not onset.

Decision‑makers in DVA must apply the instrument strictly. They should first confirm the version date and use this compilation (the latest). They must check that the claimed factor is listed in s9 and that the relationship to service is established under s10. They should not accept a claim based solely on a medical opinion that the condition is “likely related” without reference to a specific factor. The instrument’s factors are exhaustive. If the medical evidence does not mention a factor, the decision‑maker should ask for further information.

Medical practitioners giving evidence should be familiar with the instrument’s definitions. Reports should use the exact terminology: “allergic contact dermatitis” per s7(2), not simply “contact dermatitis”. They should state the allergen and, if possible, identify it from the dictionary’s examples or explain why it meets the definition. They should specify dates of exposure and onset with precision. If opining on sensitising exposure, they should distinguish between the initial exposure (asymptomatic) and the re‑exposure (symptomatic). The report should conclude whether the factor exists on the balance of probabilities.

Compliance costs include obtaining specialised dermatological assessments, which may not be covered by Medicare if the veteran is no longer serving. The Veterans’ Affairs portfolio may fund some assessments, but delay can occur. The instrument’s complexity encourages early engagement with a veterans’ advocate or lawyer who understands SoP methodology. Training on the instrument for claims staff is minimal, so representatives should supply the relevant sections in submissions. Finally, claimants should keep records of all exposures during service, even if asymptomatic, because future sensitising exposure claims may rely on those records years later.